investorscraft@gmail.com

Investor's Craft

S&P 500 Health CareS&P 500 EnergyS&P 500 Information Tech.S&P 500 Communic. ServicesS&P 500 Consumer Discret.S&P 500 Consumer StaplesS&P 500 IndustrialsS&P 500 Materials
IntroductionThe concept of valuationRevenue and revenue growthVariable costsFixed costsProduction assets

Intrinsic value of STERIS plc (STE)

Previous Close$192.31
Intrinsic Value$63.77
Upside potential  -67%
Previous Close
$192.31
Intrinsic Value
$63.77
Potential        
-67%

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh63.77 63.77

The original valuation is based on fiscal year data as of 2022-03-31 and quarterly data as of 2022-09-30.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2022(a)2023202420252026202720282029203020312032203320342035203620372038203920402041204220432044204520462047

INCOME STATEMENT

Revenue growth rate, %47.6NaN
Revenue, $4585NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m4159NaN
Operating income, $m426NaN
EBITDA, $m979NaN
Interest expense (income), $mNaN
Earnings before tax, $m316NaN
Tax expense, $m72NaN
Net income, $m244NaN

BALANCE SHEET

Cash and short-term investments, $m348NaN
Total assets, $m11424NaN
Adjusted assets (=assets-cash), $m11076NaN
Average production assets, $m7392NaN
Working capital, $m957NaN
Total debt, $m3280NaN
Total liabilities, $m4892NaN
Total equity, $m6532NaN
Debt-to-equity ratio0.502NaN
Adjusted equity ratio0.574NaN

CASH FLOW

Net income, $m244NaN
Depreciation, amort., depletion, $m553NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m667NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-286NaN
Free cash flow, $m953NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m957
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount